VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.
SHENZHEN, China, Aug. 12, 2025 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading online music...
HONG KONG, Aug. 12, 2025 /PRNewswire/ -- China Literature Limited ("China Literature" or "the Company", stock code: 0772), a leading online literature and intellectual...
SECOND QUARTER FINANCIAL RESULTS
VANCOUVER, BC, Aug. 7, 2025 /PRNewswire/ - "Wheaton delivered another outstanding quarter, achieving record revenue, adjusted net earnings, and operating cash...
SECOND QUARTER FINANCIAL RESULTS
VANCOUVER, BC, Aug. 7, 2025 /CNW/ - "Wheaton delivered another outstanding quarter, achieving record revenue, adjusted net earnings, and operating cash...
Robust Performance Across Platform Led by Midstream
CALGARY, AB, Aug. 1, 2025 /CNW/ - AltaGas Ltd. ("AltaGas" or the "Company") (TSX: ALA) reported second quarter...
MONTREAL, July 25, 2025 /CNW/ - Birks Group Inc. (the "Company" or "Birks Group") (NYSE American: BGI), today reported its financial results for the...
All figures presented herein are in Canadian dollars.
MONTREAL, July 8, 2025 /CNW/ - Birks Group Inc. (the "Company", "Birks Group" or "we") (NYSE American...